Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months.

Patients included in the study will receive Bioven, 10% solution for infusion according to the protocol for the use of IVIG in ITP - at a dose of 0.8-1.0 g / kg 1 time per day for 2 consecutive days, the course dose of 1.6-2.0 g / kg according to the "Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)", rev. 3, 28 June 2018. After administration of the investigational drug, patients will be under medical supervision for 28 days.

The stay of patients in the study - at least 4 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biopharma Plasma LLC
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Pharmaceutical Solutions; Rho(D) Immune Globulin

Criteria

Inclusion criteria:

• Signed Patient Informed Consent Form for participation in the study;

• Men and women aged 18-65;

• Confirmed primary chronic ITP (lasting > 12 months since diagnosis);

• A full blood count should be normal except for the isolated thrombocytopenia. Patients with low hemoglobin levels (but above 90 g / l) may be included if there are symptoms of bleeding;

• If bleeding symptoms are diagnosed, the reticulocyte count should be measured;

• Platelet count <30 x 109 / L;

• If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening);

• Negative pregnancy test (for women of child-bearing potential);

• Willingness to use effective and reliable methods of contraception throughout the entire study period;

• The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;

• Ability, according to the researcher, to follow all the requirements of the study protocol;

Exclusion criteria:

• Known intolerance to plasma and immunoglobulin preparations;

• Drug allergy or hypersensitivity to immunoglobulin preparations;

• Confirmed deficiency of immunoglobulin A (IgA) and antibodies to IgA.

• Contraindications to immunoglobulin administration according to the instructions for medical use;

• Pregnancy and lactation;

• Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal);

• Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;

• Severe cardiovascular insufficiency (HF III);

• History of thrombosis or presence of significant risk factors for thrombosis.

• Patients with preventive splenectomy;

• Hemostatic disorders other than chronic thrombocytopenia;

• Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;

• Proven case of primary immunodeficiency;

• Secondary immune thrombocytopenia;

• Virus infections (Epstein-Barr, Cytomegalovirus, Parvovirus, Hepatitis B and C);

• Documented HIV infection

• Positive reaction of Wassermann (RW) test result;

• Systemic immunopathological diseases (rheumatic diseases, nephritis, etc.);

• Oncological diseases;

• Diabetes mellitus;

• Thyroid diseases;

• History of mental illness;

• Known drug addiction;

• Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;

• The need to prescribe drugs that are incompatible with the administration of the drug in this study: other immunoglobulin preparations in addition to the study drug, cytostatic drugs, monoclonal antibodies, Avatrombopag);

• Experimental treatment (e.g. Rituximab therapy) for 3 months prior to screening);

• Blood transfusions or transfusions of blood products in the last 6 months prior to inclusion in the study;

• Administration of IVIG 30 days prior to screening;

• Participation in any other study currently or within the last 30 days;

Criteria for exclusion of subjects (discontinuation of treatment with the study drug):

• Patient's wish

• Occurrence of severe and/or unexpected Adverse events (AE) or Adverse reactions (AR) in patient during the study, that require discontinuation of the drug;

• The need to prescribe drugs prohibited in this study.

• Significant deterioration of the patient's condition during the study period;

• Failure of the patient to adhere to the treatment regimen;

• Failure of the patient to follow the procedures established under the protocol;